Drs. Kato and Kurzrock discuss the potential reasons why some cancer patients experience hyperprogression of disease while on immunotherapy treatment.
Shumei Kato, MD
Advertisement
Articles by Shumei Kato, MD
Advertisement
Latest Updated Articles
Razelle Kurzrock and Shumei Kato on Immunotherapy and Hyperprogression of DiseasePublished: April 15th 2018 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLC
2
Episode 16: Anticipated ESMO 2025 Data That May Change GU Oncology
3
Osimertinib/Chemo Yields OS Improvement Across Subgroups of EGFR+ NSCLC
4
Perioperative Durvalumab/NAT Chemo Does Not Improve HRQOL in MIBC
5
